Pharma Business - March 26, 2019
AstraZeneca’s Forxiga approved in Europe for type-1 diabetes
It is the first oral medicine approved in Europe as an adjunct to insulin for adults with type-1 diabetes and the first AstraZeneca medicine ever approved for type-1 diabetes. The European Commission (EC) has approved Forxiga (dapagliflozin) as an adjunct to insulin in patients with a BMI ≥ 27 kg/m2, when insulin alone does not provide adequate […]